Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Diffuse/drug therapy"'
Autor:
Toby A Eyre, Kerry J Savage, Chan Y Cheah, Tarec C El-Galaly, Katharine L Lewis, Pamela McKay, Matthew R Wilson, Andrew M Evens, Sabela Bobillo, Diego Villa, Matthew J Maurer, Kate Cwynarski, Andrés J M Ferreri
Publikováno v:
Eyre, T A, Savage, K J, Cheah, C Y, El-Galaly, T C, Lewis, K L, McKay, P, Wilson, M R, Evens, A M, Bobillo, S, Villa, D, Maurer, M J, Cwynarski, K & Ferreri, A J M 2022, ' CNS prophylaxis for diffuse large B-cell lymphoma ', The Lancet Oncology, vol. 23, no. 9, pp. e416-e426 . https://doi.org/10.1016/S1470-2045(22)00371-0
CNS relapse in the brain parenchyma, eyes, or leptomeninges is an uncommon but devastating complication of diffuse large B-cell lymphoma. CNS prophylaxis strategies, typically involving intrathecal or high-dose antimetabolites, have been developed in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9aa3c1e3efbbf620a467525e4e71a0a3
https://pubmed.ncbi.nlm.nih.gov/36055310
https://pubmed.ncbi.nlm.nih.gov/36055310
Autor:
Monique C. Minnema, Margaret A. Shipp, Stephen M. Ansell, Nishitha Reddy, Scott J. Rodig, Jonathon B. Cohen, Selda Samakoglu, Kazunobu Kato, Margaretha G.M. Roemer, Sarit Assouline, Philippe Armand, Anne Sumbul, Michelle Poon, Peter Johnson, Azra H. Ligon, Manish Sharma, John M. Timmerman, Andrew Grigg
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 37(6), 481. American Society of Clinical Oncology
Purpose Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55bd249e2e8165cc0d45938a170ea405
https://doi.org/10.1200/jco.18.00766
https://doi.org/10.1200/jco.18.00766
Autor:
Linnéa Schmidt, Issa Ismail Issa, Hulda Haraldsdóttir, Jonas Laugård Hald, Alexander Schmitz, Hanne Due, Karen Dybkær
Publikováno v:
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Schmitz, A, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
Schmidt, L, Issa, I I, Haraldsdóttir, H, Hald, J L, Due, H & Dybkær, K 2022, ' Hsp90 inhibition sensitizes DLBCL cells to cisplatin ', Cancer Chemotherapy and Pharmacology, vol. 89, no. 4, pp. 431-440 . https://doi.org/10.1007/s00280-022-04407-5
PurposePlatinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by drug resistance leading to relapse. Cisplatin resistance has been linked to impairments of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95c3d1875eb090fc0377fa24b24ad23b
https://vbn.aau.dk/ws/files/468426671/Schmidt_et_al._2022_._Hsp90_inhibition_sensitizes_DLBCL_cells_to_cisplatin.pdf
https://vbn.aau.dk/ws/files/468426671/Schmidt_et_al._2022_._Hsp90_inhibition_sensitizes_DLBCL_cells_to_cisplatin.pdf
Autor:
Wolfgang Willenbacher, Brian Fox, Peter de Nully Brown, Judit Jørgensen, Neus Domper Rubio, Marie-Laure Casadebaig, Richard Greil, Hele Everaus, Ulrich Jäger, Lorenz Trümper, David Cunningham, Oliver Manzke, Thomas Stauffer Larsen, Krish Patel, Justine Dell’Aringa, Nurgul Kilavuz, Grzegorz S. Nowakowski, Nagesh Kalakonda, Robert Manges, Javier Munoz
Publikováno v:
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell’Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Nowakowski, G S, Willenbacher, W, Greil, R, Larsen, T S, Patel, K, Jäger, U, Manges, R F, Trümper, L, Everaus, H, Kalakonda, N, Brown, P, Jørgensen, J M, Cunningham, D, Dell'Aringa, J, Fox, B, Rubio, N D, Kilavuz, N, Casadebaig, M-L, Manzke, O & Munoz, J 2022, ' Safety and efficacy of durvalumab with R-CHOP or R 2-CHOP in untreated, high-risk DLBCL : a phase 2, open-label trial ', International Journal of Hematology, vol. 115, no. 2, pp. 222-232 . https://doi.org/10.1007/s12185-021-03241-4
Patients with high-risk diffuse large B-cell lymphoma (DLBCL) have poor outcomes following first-line cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP). Evidence shows chemotherapy and immune checkpoint blockade can incre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d8c12cf157023fa610230261b321fc
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009
https://portal.findresearcher.sdu.dk/da/publications/a1eda3b7-edc6-42d6-9940-c2ac96b43009
Autor:
Lasse Hjort Jakobsen, Andreas Kiesbye Øvlisen, Marianne Tang Severinsen, Joachim Bæch, Kristian Hay Kragholm, Ingrid Glimelius, Anne Ortved Gang, Judit Mészáros Jørgensen, Henrik Frederiksen, Christian Bjørn Poulsen, Michael Roost Clausen, Per Trøllund Pedersen, Robert Schou Pedersen, Christian Torp-Pedersen, Sandra Eloranta, Tarec Christoffer El-Galaly
Publikováno v:
Jakobsen, L H, Øvlisen, A K, Severinsen, M T, Bæch, J, Kragholm, K H, Glimelius, I, Gang, A O, Jørgensen, J M, Frederiksen, H, Poulsen, C B, Clausen, M R, Pedersen, P T, Pedersen, R S, Torp-Pedersen, C, Eloranta, S & El-Galaly, T C 2022, ' Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark ', Blood Cancer Journal, vol. 12, no. 1, 16 . https://doi.org/10.1038/s41408-022-00614-8
Blood Cancer Journal
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-7 (2022)
Jakobsen, L H, Øvlisen, A K, Severinsen, M T, Bæch, J, Kragholm, K H, Glimelius, I, Gang, A O, Jørgensen, J M, Frederiksen, H, Poulsen, C B, Clausen, M R, Pedersen, P T, Pedersen, R S, Torp-Pedersen, C, Eloranta, S & El-Galaly, T C 2022, ' Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark ', Blood Cancer Journal, vol. 12, 16 . https://doi.org/10.1038/s41408-022-00614-8
Jakobsen, L H, Ovlisen, A K, Severinsen, M T, Baech, J, Kragholm, K H, Glimelius, I, Gang, A O, Jorgensen, J M, Frederiksen, H, Poulsen, C B, Clausen, M R, Pedersen, P T, Pedersen, R S, Torp-Pedersen, C, Eloranta, S & El-Galaly, T C 2022, ' Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark ', Blood Cancer Journal, vol. 12, no. 1, 16 . https://doi.org/10.1038/s41408-022-00614-8
Blood Cancer Journal
Blood Cancer Journal, Vol 12, Iss 1, Pp 1-7 (2022)
Jakobsen, L H, Øvlisen, A K, Severinsen, M T, Bæch, J, Kragholm, K H, Glimelius, I, Gang, A O, Jørgensen, J M, Frederiksen, H, Poulsen, C B, Clausen, M R, Pedersen, P T, Pedersen, R S, Torp-Pedersen, C, Eloranta, S & El-Galaly, T C 2022, ' Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark ', Blood Cancer Journal, vol. 12, 16 . https://doi.org/10.1038/s41408-022-00614-8
Jakobsen, L H, Ovlisen, A K, Severinsen, M T, Baech, J, Kragholm, K H, Glimelius, I, Gang, A O, Jorgensen, J M, Frederiksen, H, Poulsen, C B, Clausen, M R, Pedersen, P T, Pedersen, R S, Torp-Pedersen, C, Eloranta, S & El-Galaly, T C 2022, ' Patients in complete remission after R-CHOP(-like) therapy for diffuse large B-cell lymphoma have limited excess use of health care services in Denmark ', Blood Cancer Journal, vol. 12, no. 1, 16 . https://doi.org/10.1038/s41408-022-00614-8
For most patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL), R-CHOP immunochemotherapy leads to complete remission and 60–70% of patients remain progression-free after 5 years. Given a median age of 65, it is relevant to disentangl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7611d7de63550fde1e34623f58f2393f
https://vbn.aau.dk/ws/files/461184201/Jakobsen_et_al._2022_._Patients_in_complete_remission_after_R_CHOP_like_therapy_for_diffuse_large_B_cell_lymphoma_have_limited_excess_use_of_health_care_services_in_Denmark.pdf
https://vbn.aau.dk/ws/files/461184201/Jakobsen_et_al._2022_._Patients_in_complete_remission_after_R_CHOP_like_therapy_for_diffuse_large_B_cell_lymphoma_have_limited_excess_use_of_health_care_services_in_Denmark.pdf
Autor:
Zijun Y. Xu-Monette, Li Wei, Xiaosheng Fang, Qingyan Au, Harry Nunns, Máté Nagy, Alexandar Tzankov, Feng Zhu, Carlo Visco, Govind Bhagat, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Fredrick B. Hagemeister, Xiaoping Sun, Xin Han, Heounjeong Go, Maurilio Ponzoni, Andrés J.M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Yong Li, Bing Xu, Maher Albitar, Hua You, Ken H. Young
Publikováno v:
Xu-Monette, Z Y, Wei, L, Fang, X, Au, Q, Nunns, H, Nagy, M, Tzankov, A, Zhu, F, Visco, C, Bhagat, G, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Sun, X, Han, X, Go, H, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B, Albitar, M, You, H & Young, K H 2022, ' Genetic subtyping and phenotypic characterization of the immune microenvironment and MYC/BCL2 double expression reveal heterogeneity in diffuse large B-cell lymphoma ', Clinical Cancer Research, vol. 28, no. 5, pp. 972-983 . https://doi.org/10.1158/1078-0432.CCR-21-2949
Clin Cancer Res
Xu-Monette, Z Y, Wei, L, Fang, X, Au, Q, Nunns, H, Nagy, M, Tzankov, A, Zhu, F, Visco, C, Bhagat, G, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Sun, X, Han, X, Go, H, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B, Albitar, M, You, H & Young, K H 2022, ' Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma ', Clinical Cancer Research, vol. 28, no. 5, pp. 972-983 . https://doi.org/10.1158/1078-0432.CCR-21-2949
Clinical Cancer Research, 28, 5, pp. 972-983
Clinical Cancer Research, 28, 972-983
Clin Cancer Res
Xu-Monette, Z Y, Wei, L, Fang, X, Au, Q, Nunns, H, Nagy, M, Tzankov, A, Zhu, F, Visco, C, Bhagat, G, Dybkaer, K, Chiu, A, Tam, W, Zu, Y, Hsi, E D, Hagemeister, F B, Sun, X, Han, X, Go, H, Ponzoni, M, Ferreri, A J M, Møller, M B, Parsons, B M, van Krieken, J H, Piris, M A, Winter, J N, Li, Y, Xu, B, Albitar, M, You, H & Young, K H 2022, ' Genetic Subtyping and Phenotypic Characterization of the Immune Microenvironment and MYC/BCL2 Double Expression Reveal Heterogeneity in Diffuse Large B-cell Lymphoma ', Clinical Cancer Research, vol. 28, no. 5, pp. 972-983 . https://doi.org/10.1158/1078-0432.CCR-21-2949
Clinical Cancer Research, 28, 5, pp. 972-983
Clinical Cancer Research, 28, 972-983
Purpose: Diffuse large B-cell lymphoma (DLBCL) is molecularly and clinically heterogeneous, and can be subtyped according to genetic alterations, cell-of-origin, or microenvironmental signatures using high-throughput genomic data at the DNA or RNA le
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff3b7f24b6809af89564b81b40855894
https://doi.org/10.1158/1078-0432.CCR-21-2949
https://doi.org/10.1158/1078-0432.CCR-21-2949
Autor:
Umar Farooq, Carrie A. Thompson, David Cunningham, Judit Jørgensen, John F. Seymour, Francesco Merli, Gilles Salles, Corinne Haioun, Qian Shi, Cristopher R. Flowers, Thomas M. Habermann, Matthew J. Maurer, Peter de Nully Brown, Viola Poeschel, Hervé Tilly, Hervé Ghesquières, Raphael Mwangi, Lasse Hjort Jakobsen, Grzegorz S. Nowakowski, Norbert Schmitz, Henrik Frederiksen, Tarec Christoffer El-Galaly, Marita Ziepert
Publikováno v:
Am J Hematol
Maurer, M J, Jakobsen, L H, Mwangi, R, Schmitz, N, Farooq, U, Flowers, C R, de Nully Brown, P, Thompson, C A, Frederiksen, H, Cunningham, D, Jørgensen, J, Poeschel, V, Nowakowski, G, Seymour, J F, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, T C & Habermann, T M 2021, ' Relapsed / Refractory International Prognostic Index (R/R-IPI) : An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma ', American Journal of Hematology, vol. 96, no. 5, pp. 599-605 . https://doi.org/10.1002/ajh.26149
Maurer, M J, Jakobsen, L H, Mwangi, R, Schmitz, N, Farooq, U, Flowers, C R, de Nully Brown, P, Thompson, C A, Frederiksen, H, Cunningham, D, Jørgensen, J, Poeschel, V, Nowakowski, G, Seymour, J F, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, T C & Habermann, T M 2021, ' Relapsed/Refractory International Prognostic Index (R/R-IPI) : An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma ', American Journal of Hematology, vol. 96, no. 5, pp. 599-605 . https://doi.org/10.1002/ajh.26149
Maurer, M J, Jakobsen, L H, Mwangi, R, Schmitz, N, Farooq, U, Flowers, C R, de Nully Brown, P, Thompson, C A, Frederiksen, H, Cunningham, D, Jørgensen, J, Poeschel, V, Nowakowski, G, Seymour, J F, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, T C & Habermann, T M 2021, ' Relapsed / Refractory International Prognostic Index (R/R-IPI) : An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma ', American Journal of Hematology, vol. 96, no. 5, pp. 599-605 . https://doi.org/10.1002/ajh.26149
Maurer, M J, Jakobsen, L H, Mwangi, R, Schmitz, N, Farooq, U, Flowers, C R, de Nully Brown, P, Thompson, C A, Frederiksen, H, Cunningham, D, Jørgensen, J, Poeschel, V, Nowakowski, G, Seymour, J F, Merli, F, Haioun, C, Ghesquieres, H, Ziepert, M, Tilly, H, Salles, G, Shi, Q, El-Galaly, T C & Habermann, T M 2021, ' Relapsed/Refractory International Prognostic Index (R/R-IPI) : An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma ', American Journal of Hematology, vol. 96, no. 5, pp. 599-605 . https://doi.org/10.1002/ajh.26149
Disease progression after frontline therapy for Diffuse large B-cell lymphoma (DLBCL) is a clinically significant event. Patients who experience early progression or have refractory disease have especially poor outcomes. Simple, clinically applicable
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d42d988e420a248fcb90d67e5f3c76af
https://pubmed.ncbi.nlm.nih.gov/33661547
https://pubmed.ncbi.nlm.nih.gov/33661547
Autor:
Roger Hesselstrand, Reinhard E. Voll, Ellen De Langhe, Per Ljungman, Jeska K de Vries-Bouwstra, Madelon C. Vonk, Vanessa Smith, Miro Mayer, Anne C. A. Marijnissen, Jacob M van Laar, Nicoletta Del Papa, Karina Roxana Gheorghe, Paco M. W. Welsing, Anna van Rhenen, Dirk M. Wuttge, Roland Schroers, Tessa Kerre, Erik W.A. Marijt, Julia Spierings, Marc Schmalzing, Arjan A. van de Loosdrecht, Joerg Henes, Ulrich A. Walker, Alexandre E Voskuyl, Daan Dierickx
Publikováno v:
BMJ Open, 11
BMJ Open, 11(3). BMJ PUBLISHING GROUP
BMJ Open, 11, 3
BMJ Open, 11(3):e044483. BMJ Publishing Group
BMJ Open, Vol 11, Iss 3 (2021)
BMJ OPEN
Spierings, J, van Rhenen, A, Welsing, P M W, Marijnissen, A C A, de Langhe, E, del Papa, N, Dierickx, D, Gheorghe, K R, Henes, J, Hesselstrand, R, Kerre, T, Ljungman, P, van de Loosdrecht, A A, Marijt, E W A F, Mayer, M, Schmalzing, M, Schroers, R, Smith, V, Voll, R E, Vonk, M C, Voskuyl, A E, de Vries-Bouwstra, J K, Walker, U A, Wuttge, D M & van Laar, J M 2021, ' A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: The UPSIDE study protocol ', BMJ Open, vol. 11, no. 3, e044483 . https://doi.org/10.1136/bmjopen-2020-044483
BMJ Open
BMJ Open, 11(3). BMJ PUBLISHING GROUP
BMJ Open, 11, 3
BMJ Open, 11(3):e044483. BMJ Publishing Group
BMJ Open, Vol 11, Iss 3 (2021)
BMJ OPEN
Spierings, J, van Rhenen, A, Welsing, P M W, Marijnissen, A C A, de Langhe, E, del Papa, N, Dierickx, D, Gheorghe, K R, Henes, J, Hesselstrand, R, Kerre, T, Ljungman, P, van de Loosdrecht, A A, Marijt, E W A F, Mayer, M, Schmalzing, M, Schroers, R, Smith, V, Voll, R E, Vonk, M C, Voskuyl, A E, de Vries-Bouwstra, J K, Walker, U A, Wuttge, D M & van Laar, J M 2021, ' A randomised, open-label trial to assess the optimal treatment strategy in early diffuse cutaneous systemic sclerosis: The UPSIDE study protocol ', BMJ Open, vol. 11, no. 3, e044483 . https://doi.org/10.1136/bmjopen-2020-044483
BMJ Open
IntroductionSystemic sclerosis (SSc) is a chronic, autoimmune connective tissue disease associated with high morbidity and mortality, especially in diffuse cutaneous SSc (dcSSc). Currently, there are several treatments available in early dcSSc that a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe321de3f3691e61f10c0c390a3e5bd
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/232577
https://hdl.handle.net/https://repository.ubn.ru.nl/handle/2066/232577
Autor:
Joanna M Oladipo, Hannah Plaschkes, Paul Fields, Arief Gunawan, Amy A Kirkwood, John Willan, Bing Tseu, Catherine Hildyard, Tim Ebsworth, Lucia Chen, Usman Khan, Robert Lown, Joe Browning, Adam Gibb, Patrick Horgan, Julia Wolf, Kim Linton, Jaimal Kothari, Dominic Gordon-Walker, Nimish Shah, Claire Higham, Graham P. Collins, Stephen Booth, Toby A. Eyre
Publikováno v:
Booth, S, Plaschkes, H, Kirkwood, A A, Gibb, A, Horgan, P, Higham, C, Oladipo, J M, Browning, J, Khan, U, Tseu, B, Chen, L, Willan, J, Wolf, J, Gunawan, A, Fields, P, Ebsworth, T, Lown, R, Gordon-Walker, D, Shah, N, Linton, K M, Collins, G P, Kothari, J, Hildyard, C & Eyre, T A 2020, ' Fractures are common within 18 months following first-line R-CHOP in older patients with diffuse large B-cell lymphoma ', Blood Advances, vol. 4, no. 18, pp. 4337-4346 . https://doi.org/10.1182/BLOODADVANCES.2020002553
Blood Adv
Blood Adv
Diffuse large B-cell lymphoma (DLBCL) and osteoporotic fracture are both more common in older patients. Exposure to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone) is likely to increase the risk of fracture, but evide
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5bc9701b57b526dc42a68d328f065ff7
https://research.manchester.ac.uk/en/publications/eb959c06-89d1-46b1-aa0f-dda1a7688dd4
https://research.manchester.ac.uk/en/publications/eb959c06-89d1-46b1-aa0f-dda1a7688dd4
Autor:
Thomas Creasey, Nimish Shah, Jeremy Schofield, Kate Cwynarski, Matthew R. Wilson, Jeffery Smith, Toby A. Eyre, Cheuk Kie Cheung, Fiona Miall, Kim Linton, Katrina Parsons, Christopher P. Fox, Gavin Preston, Pamela McKay, Matthew J. Ahearne, Matthew A. Timmins, Almurtadha Mula Kh, Jahanzaib Khwaja, Nicolas Martinez-Calle, Johnathon Elliot
Publikováno v:
Blood Adv
Wilson, M R, Eyre, T A, Martinez-Calle, N, Ahearne, M, Parsons, K E, Preston, G, Khwaja, J, Schofield, J, Elliot, J, Kh, A M, Shah, N, Cheung, C K, Timmins, M A, Creasey, T, Linton, K, Smith, J, Fox, C P, Miall, F, Cwynarski, K & McKay, P 2020, ' Timing of high-dose methotrexate CNS prophylaxis in DLBCL : An analysis of toxicity and impact on R-CHOP delivery ', Blood Advances, vol. 4, no. 15, pp. 3586-3593 . https://doi.org/10.1182/bloodadvances.2020002421
Wilson, M R, Eyre, T A, Martinez-Calle, N, Ahearne, M, Parsons, K E, Preston, G, Khwaja, J, Schofield, J, Elliot, J, Kh, A M, Shah, N, Cheung, C K, Timmins, M A, Creasey, T, Linton, K, Smith, J, Fox, C P, Miall, F, Cwynarski, K & McKay, P 2020, ' Timing of high-dose methotrexate CNS prophylaxis in DLBCL : An analysis of toxicity and impact on R-CHOP delivery ', Blood Advances, vol. 4, no. 15, pp. 3586-3593 . https://doi.org/10.1182/bloodadvances.2020002421
High-dose methotrexate (HD-MTX) is increasingly used as prophylaxis for patients with diffuse large B-cell lymphoma (DLBCL) at high risk of central nervous system (CNS) relapse. However, there is limited evidence to guide whether to intercalate HD-MT
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6a2409dbd0bd720cf92cdf284785ac8
https://pubmed.ncbi.nlm.nih.gov/32761231
https://pubmed.ncbi.nlm.nih.gov/32761231